Clinical Scorecard: Evolving Perspectives on Pediatric EBMT Criteria

At a Glance

Key Highlights

• Pediatric EBMT (pEBMT) criteria address limitations of Seattle and Baltimore criteria by including anicteric VOD/SOS and transfusion refractory thrombocytopenia (TRT).
• Early diagnosis using pEBMT criteria enables preemptive treatment with defibrotide, improving survival and reducing morbidity.
• Retrospective studies show pEBMT criteria diagnose VOD/SOS 2.5–3 days earlier with higher sensitivity and specificity compared to older criteria.

Guideline-Based Recommendations

Diagnosis

• Use pEBMT criteria for pediatric VOD/SOS diagnosis, incorporating anicteric presentations and TRT as sensitive early markers.
• Establish precise pre-HSCT baseline measures including ultrasound to differentiate pre-existing hepatomegaly and ascites.
• Recognize that hyperbilirubinemia may develop days after diagnosis; do not rely solely on bilirubin thresholds.

Management

• Initiate early/preemptive treatment with defibrotide upon diagnosis according to pEBMT criteria to improve outcomes.
• Consider timing of defibrotide intervention critical; earlier treatment correlates with superior survival and reduced morbidity.

Monitoring & Follow-up

• Monitor for transfusion refractory thrombocytopenia as an early sensitive indicator of VOD/SOS.
• Perform regular clinical assessments including weight, liver size, ascites, and bilirubin levels post-HSCT.
• Use baseline and follow-up ultrasound imaging to assess hepatomegaly and ascites.

Risks

• Delayed diagnosis due to reliance on hyperbilirubinemia or outdated criteria may worsen outcomes.
• Pre-existing conditions such as hemophagocytic lymphohistiocytosis or hemoglobinopathies may confound clinical signs.
• Retrospective data suggest need for prospective validation of pEBMT criteria.

Patient & Prescribing Data

Pediatric patients undergoing HSCT at risk for SOS/VOD

Defibrotide is authorized by the European Medicines Agency for SOS/VOD treatment; early initiation per pEBMT criteria improves survival and reduces transplant-related morbidity.

Clinical Best Practices

• Adopt pEBMT criteria for earlier and more sensitive diagnosis of pediatric SOS/VOD.
• Incorporate transfusion refractory thrombocytopenia as a key diagnostic and severity marker.
• Establish pre-transplant baseline clinical and imaging assessments to improve diagnostic accuracy.
• Implement early defibrotide treatment guided by pEBMT criteria to optimize patient outcomes.
• Recognize the need for prospective studies to confirm retrospective findings and refine criteria.

References

• European Society for Blood and Marrow Transplantation (EBMT) pediatric criteria
• Embaby et al. study on refractory thrombocytopenia as early marker
• Szmit et al. prospective comparison of Seattle and pEBMT criteria
• Ragoonanan et al. retrospective comparison of VOD/SOS diagnostic criteria